[From cardiovascular risk to chronic heart failure].
Ertl
Georg
G
Medizinische Universitätsklinik Würzburg.
D020909:Acarbose / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000503:physiopathology*; D003331:Coronary Vessels / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000503:physiopathology; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006333:Heart Failure / Q000175:diagnosis / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D006943:Hyperglycemia / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D006949:Hyperlipidemias / Q000175:diagnosis / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology*; D009203:Myocardial Infarction / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control; D018487:Ventricular Dysfunction, Left / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control
D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents; D020909:Acarbose